Hoping to bag the ResMed dividend? You better be quick!

Is a healthy dividend on the way?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It won't be long before the next Resmed CDI (ASX: RMD) dividend is on its way to shareholders. If investors want to gain access to the payout, they'll need to be quick because it's nearly deadline day!

The ex-dividend date is one of the most important dates when it comes to dividend investing. Investors need to own shares before the ex-dividend date to gain entitlement to the upcoming payment. If investors buy on the ex-dividend date (or afterwards), they'll miss out.

A businessman holding a butterfly net looks around hoping to snare a good ASX share investment

Image source: Getty Images

Resmed ex-dividend date

The ex-dividend date for the imminent quarterly payment is on Wednesday, 7 February. That means, to ensure entitlement to this upcoming dividend, investors will need to own Resmed shares by the end of trading tomorrow, 6 February.

The ASX healthcare share is planning to pay this dividend of US 4.8 cents per share on 14 March 2024.

At the current foreign exchange rate, that would translate into a payment of AU 7.3 cents per share. Resmed will provide further details about the size of the dividend in Australian dollar terms on Friday, 9 February.

Profitability performance

Resmed recently announced its FY24 second quarter performance for the three months to 31 December 2023.

It reported that revenue increased by 12% to $1.2 billion, the underlying gross profit margin improved 10 basis points to 56.9%, the underlying (non-GAAP) operating profit improved 20%, and it made an operating cash flow of $272.8 million.

You can read more about that update from our coverage of the quarter.

Management said strong growth in patient flow over the past several quarters had "supported ongoing device growth" and added to replenishment programs for "sustained mask and accessories growth". It was also launching its latest generation platform, AirSense 11, into new markets and geographies.

Resmed share price snapshot

The Resmed share price has fallen more than 8% over the past year.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

Down 43% this week, are Cochlear shares now the best bargain buy of the year?

A leading analyst believes the historic selloff in Cochlear shares could present a unique buying opportunity.

Read more »

Young businesswoman sitting in kitchen and working on laptop.
Healthcare Shares

Down 50%, why I'd invest $20,000 into CSL shares

A 50% decline in a blue-chip share can signal trouble, but not always a broken story.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

This ASX biotech stock could deliver 40%-plus returns Morgans says

This small company continues to kick goals.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Healthcare Shares

How high could Cochlear shares bounce back? Brokers disagree

Despite bad news on the earnings front this week, Cochlear shares could still deliver upside.

Read more »

Retired couple hugging and laughing.
Healthcare Shares

A Budget announcement has put a rocket under this ASX aged care provider's shares

A shake up in the funding model will be a boost for this company.

Read more »

An arrow crashes through the ground as a businessman watches on.
Healthcare Shares

Cochlear stock down 40%: How much has this cost ASX investors?

One day can ruin years of success...

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

What on earth's going on with Pro Medicus shares?

The quality stock is now driven heavily by expectations.

Read more »

A stressed businessman sits next to his briefcase with his head in his hands, while the ASX boards behind him show shares crashing.
52-Week Lows

CSL's collapse deepens. Why this ASX giant can't find a floor

CSL shares hit a 9-year low as new demand concerns emerge.

Read more »